|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
|
25962792 |
2015 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant anaplastic astrocytomas and secondary glioblastomas.
|
27626492 |
2016 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Astrocytoma (grade III) are frequently mutated in isocitrate dehydrogenase (IDH1).
|
31039537 |
2019 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, IDH mutation would be most useful when assessing prognosis of patients with grade 3 glioma with intact 1p/19q; anaplastic astrocytomas account for most of these grade 3 gliomas.
|
22136423 |
2012 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To validate mutation frequency, IDH1 gene at codon 132 was sequenced in 74 diffusely infiltrating astrocytomas: diffuse astrocytoma (DA; World Health Organization [WHO] grade II), anaplastic astrocytoma (AA; WHO grade III), and GBM (WHO grade IV).
|
22904127 |
2012 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 ± 14 years) and used to extract individual level, gray matter connectomes.
|
27848136 |
2017 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study confirms the utility of IDH1 mutations and MGMT methylation in predicting the prognosis of Group 1 patients (GBM + AA) and demonstrated that IDH1 mutations may serve as a more reliable prognostic factor for such patients.
|
24160898 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We here report neuroimaging findings in a 69-year-old man with a "butterfly" pattern on dynamic FET [O-(2-[F]-fluoroethyl)-L-tyrosine] PET and the diagnosis of an anaplastic astrocytoma (WHO grade III; IDH-1/-2 wildtype, no 1p/19q co-deletion) but without typical MRI contrast enhancement.
|
31348085 |
2019 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas.
|
19765000 |
2009 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A second surgery was performed, and pathology demonstrated recurrent tumor, consistent with IDH1-mutated anaplastic astrocytoma.
|
26911558 |
2016 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
|
19554337 |
2009 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To characterize the contribution of wild-type IDH1 to cancer cell D-2HG production, we established an IDH1-mutated astrocytoma (IMA) cell line from a WHO grade III anaplastic astrocytoma.
|
23204232 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis demonstrated that T2-EOR (HR 3.28; 95% CI 1.22-8.81; p = 0.0192) and IDH1 mutation (HR 3.90; 95% CI 1.53-10.75; p = 0.0044) were predictive of survival in patients with AA and AOA.
|
28885120 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
|
24748470 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutations are frequent (>80%) in secondary glioblastomas that have progressed from low-grade or anaplastic astrocytomas.
|
21442241 |
2011 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prevalences of mutations of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A), the glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and methylation of alkylpurine DNA N-glycosylase (APNG) and peroxiredoxin 1 (PRDX1) promoters were determined in a representative biomarker subset (n = 126 patients with anaplastic astrocytoma or glioblastoma) from the NOA-08 trial.
|
23595628 |
2013 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To establish the frequency of IDH1 mutations in glioblastomas at a population level, and to assess whether they allow reliable discrimination between primary (de novo) glioblastomas and secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma.
|
19755387 |
2009 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
|
Anaplastic astrocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.
|
24305719 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IHC detected the IDH1 mutation in 72% (13/18) anaplastic astrocytomas and 30% (3/10) astrocytomas; however, it failed to detect the mutation in 258 thyroid, 11 renal cell, 10 ovarian, 18 endometrial, 20 breast, 25 colorectal, 22 non-small cell lung carcinoma, 25 melanomas, and 8 thyroid follicular adenomas.
|
23235339 |
2014 |
|
Anaplastic astrocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An important underlying observation was that patients with anaplastic astrocytomas (AA) without IDH mutation had a clinical course similar to that of patients with glioblastomas (GBM).
|
31623667 |
2019 |